MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

PTC Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

64.42 1.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

63.04

Max

65.15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-931M

-65M

Verkäufe

-997M

179M

KGV

Branchendurchschnitt

9.192

37.257

Gewinnspanne

-36.254

Angestellte

939

EBITDA

-1B

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+3.08% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1B

5.1B

Vorheriger Eröffnungskurs

63.37

Vorheriger Schlusskurs

64.42

Nachrichtenstimmung

By Acuity

37%

63%

151 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

PTC Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Juli 2025, 16:40 UTC

Wichtige Markttreiber

PTC Therapeutics Gains on FDA Approval for Blood-Disorder Treatment

2. Dez. 2024, 12:47 UTC

Wichtige Markttreiber

PTC Therapeutics Shares Jump on Pact With Novartis

Peer-Vergleich

Kursveränderung

PTC Therapeutics Inc Prognose

Kursziel

By TipRanks

3.08% Vorteil

12-Monats-Prognose

Durchschnitt 65.87 USD  3.08%

Hoch 118 USD

Tief 44 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für PTC Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

11

Buy

5

Halten

1

Sell

Technischer Score

By Trading Central

40.81 / 50.39Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

151 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat